BioWorld - Tuesday, February 10, 2026

BioWorld Science

Aug. 6, 2021

View Archived Issues

Positive phase II data published from GENETIC-AF study of bucindolol in patients with heart failure

Read More

Syros enters clinical supply agreement with Roche to evaluate SY-5609 as part of INTRINSIC study

Read More

Enanta nominates EDP-235 as clinical candidate for the treatment of COVID-19

Read More

Suzhou Zelgen Biosciences discovers G12C mutant GTPase KRAS inhibitors

Read More

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent cereblon ligands

Read More

Hisun Accuray Therapeutics, Zhejiang Hisun Pharmaceutical present SHP-2 inhibitors

Read More

New thyroid hormone receptor agonists divulged by Eccogene

Read More

Aptahem reports positive preliminary results from GLP studies of Apta-1

Read More

Enrollment begins in phase II study of Stemedica's itMSCs in patients with COVID-19

Read More

Exicure provides updated interim data from phase Ib/II study of cavrotolimod

Read More

INPP5D inhibition reduces amyloid pathology in Alzheimer's disease model

Read More

First patient dosed in IMP-MEL study of PORT-2 for the treatment of melanoma and NSCLC

Read More

Clene provides topline data from REPAIR-PD and REPAIR-MS studies

Read More

MYMD-1 shows the ability to suppress cytokine storm in human cells

Read More

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Read More

Dosing begins in phase II portion of phase I/II trial of AKS-452

Read More

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Read More

Enrollment starts in phase I study of ZYIL-1

Read More

Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia

Read More

Labile iron pool radiotracer [18F]TRX can predict sensitivity to iron-targeted tumor therapies

Read More

GI Innovation begins patient enrollment in phase I/II study of GI-101

Read More

Enrollment ongoing in first-in-human study of [68Ga]-FF58

Read More